Packing batteries with more punch
Indian researchers are working on cells that can store more energy, last longer
According to the SERB official, academic and research institutions with strong interdisciplinary links with chemists, biologists, virologists, immunologists and clinicians can apply for the IRHPA funding
Indian pharma companies and research groups in different scientific laboratories are working on as many as 30 different novel Coronavirus (nCoV-19) vaccines, and a few of them are expected to move into clinical trials later this year.
While taking stock of India’s efforts in developing corona vaccines, drugs and diagnostics on Tuesday, Prime Minister Narendra Modi said that nearly 30 Indian vaccines are getting ready. While there are that many, those few in advanced stages of development are mainly those vaccines on which most initial developmental work was carried out elsewhere, shows information sourced from multiple sources.
For instance, the Pune-based Serum Institute is a manufacturing partner for a promising vaccine developed by the University of Oxford. Called ChAdOx1 nCoV-19, the vaccine uses a weakened version of the virus that causes the common cold in chimpanzees to carry particular genetic material from SARS-CoV2 virus which makes proteins that help the Covid-19 virus to human cells. The vaccine is already undergoing limited clinical trials in Oxford and is in an advanced stage of development.
Serum Institute is also involved in the development of three other nCoV-19 vaccines in collaboration with overseas firms or research institutes and one of them, a live attenuated vaccine, is expected to go to phase 1 trials in the third quarter of 2020.
Similarly, Hyderabad-based BharatBiotech International Limited in association with two US universities – the University of Wisconsin-Madison and Thomas Jefferson University -- is developing two different vaccines. The one jointly developed with the University of Wisconsin-Madison is a nasal vaccine and is expected to go to trials by later part of this year. The other which uses a rabies vaccine platform is also expected to hit Phase 1 trials by December this year.
Similarly, a major Indian pharma company Cadila Healthcare is gearing up to test a DNA vaccine for COVID-19 by November this year. Indian Immunological Limited, a subsidiary of National Dairy Development Board, similarly has a tie-up with Australian Griffith University, but this live attenuated vaccine will not be ready for testing till mid-2022.
Among other Indian pharma firms collaborating with overseas teams are Aurobindo Pharma Limited which tied up with Aurovaccines US and Biological E which is working with a team at Massachusetts Institute of Technology. There are a few lesser-known pharma firms and startups too in the nCoV vaccine fray, but most of them are in the early stages of development.
Besides these firms, many research groups in Indian laboratories such as National Institute of Immunology, New Delhi, Translational Health Science and Technology Institute, in Faridabad, National Centre for Cell Sciences, Pune, Indian Institute of Science Education and Research in Mohali as well as Thiruvananthapuram too are developing indigenous vaccines. However, they are very early stages of development.
Indian researchers are working on cells that can store more energy, last longer
To fix a broken bone, doctors often harvest another bone from the patient’s body or from someone else. It ...
Superconductors from IIScScientists at IISc Bangalore have invented a device with a nanocrystal structure ...
Engineering and construction giant L&T has won a licence from the Council of Scientific & Industrial ...
Option price falls more than it rises for the same change in underlying
A long-term vacation here is worth a check-in
The fund delivered a return of 31.5% in 2020 compared with the category’s 15.5%
Care Health Insurance’s new rider offers no great benefit. We review its pros and cons
In these isolated times when people yearn for a slice of the familiar, amateur and professional chefs are ...
While good writing wars against the cliché, television gives it a natural home
India is ready with two vaccines to beat the deadliest virus of recent times. The immunisation drive, however, ...
The storming of the Capitol on January 6 could be the prelude to yet another chapter in the US’s long and ...
Digital is becoming dominant media, but are companies and their ad agencies transforming fast enough to make a ...
Slow Network, promoted by journalist-lyricist Neelesh Misra, pushes rural products and experiences
How marketers can use the traditional exchange of festive wishes meaningfully
For Fortune, a brand celebrating its 20th anniversary, it was a rude shock to become the butt of social media ...
Three years after its inception, compliance with GST procedures remains a headache for exporters, job workers ...
Corporate social responsibility (CSR) initiatives of companies are altering the prospects for wooden toys of ...
Aequs Aerospace to create space for large-scale manufacture of toys at Koppal
And it has every reason to smile. Covid-19 has triggered a consumer shift towards branded products as ...
Please Email the Editor